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Genetic screens are powerful tools for identifying
genes responsible for diverse phenotypes. Here we
describe a genome-wide CRISPR/Cas9-mediated
loss-of-function screen in tumor growth and metas-
tasis. We mutagenized a non-metastatic mouse can-
cer cell line using a genome-scale library with 67,405
single-guide RNAs (sgRNAs). The mutant cell pool
rapidly generates metastases when transplanted
into immunocompromised mice. Enriched sgRNAs
in lung metastases and late-stage primary tumors
were found to target a small set of genes, suggesting
that specific loss-of-function mutations drive tumor
growth and metastasis. Individual sgRNAs and a
small pool of 624 sgRNAs targeting the top-scoring
genes from the primary screen dramatically accel-
erate metastasis. In all of these experiments, the ef-
fect of mutations on primary tumor growth positively
correlates with the development of metastases. Our
study demonstrates Cas9-based screening as a
robust method to systematically assay gene pheno-
types in cancer evolution in vivo.
INTRODUCTION
Cancer genomes have complex landscapes of mutations and
diverse types of genetic aberrations (Lawrence et al., 2013;
Weinberg, 2007). A major challenge in understanding the cancer
genome is to disentangle alterations that are driving the pro-
cesses of tumor evolution from passenger mutations (Garraway
and Lander, 2013). Primary tumor growth and metastasis are
distinct yet linked processes in the progression of solid tumors
(Nguyen et al., 2009; Valastyan andWeinberg, 2011; Vanharanta
and Massague´, 2013). It has been observed in the clinic that the1246 Cell 160, 1246–1260, March 12, 2015 ª2015 Elsevier Inc.probability of detecting metastases in a patient correlates posi-
tively with the size of a primary tumor (Heimann and Hellman,
1998). Several possible explanations have been suggested: met-
astatic properties may only be acquired in late-stage tumors,
larger tumors may seed proportionally more cells into circulation
that eventually migrate to other sites, or cells with a strong ability
to proliferate may also have enhanced ability to metastasize
(Weinberg, 2007). In early studies using random insertional
mutagenesis, it was observed that metastatic cell subpopula-
tions overgrow to complete dominance in the primary tumor,
suggesting progressive selection at both sites (Korczak et al.,
1988; Waghorne et al., 1988).
Genetic screens are powerful tools for assaying phenotypes
and identifying causal genes in various hallmarks of cancer pro-
gression (Hanahan andWeinberg, 2011). RNAi and overexpres-
sion of open reading frames (ORFs) have been utilized for
screening cancer genes in several models of oncogenesis in
mice (Schramek et al., 2014; Shao et al., 2014; Zender et al.,
2008). Recently, the Cas9 nuclease (Barrangou et al., 2007; Bo-
lotin et al., 2005; Chylinski et al., 2013, 2014; Deltcheva et al.,
2011; Garneau et al., 2010; Gasiunas et al., 2012; Jinek et al.,
2012; Sapranauskas et al., 2011) from the microbial type II
CRISPR (clustered regularly interspaced short palindromic re-
peats) system has been harnessed to facilitate loss-of-function
mutations in eukaryotic cells (Cong et al., 2013; Mali et al.,
2013). When the Cas9 nuclease is targeted to specific locations
in the genome, DNA cleavage results in double-stranded
breaks (DSBs), which are repaired via non-homologous end-
joining (NHEJ) (Rouet et al., 1994). NHEJ repair results in inser-
tion or deletion (indel) mutations that can cause loss of function
if the DSB occurs in a coding exon. The Cas9 nuclease can be
guided to its DNA target by a single-guide RNA (sgRNA) (Jinek
et al., 2012), a synthetic fusion between the CRISPR RNA
(crRNA) and trans-activating crRNA (tracrRNA) (Deltcheva
et al., 2011). In cells, Cas9-mediated gene disruption requires
the full-length tracrRNA (Cong et al., 2013; Mali et al., 2013),
in which secondary structures at the 30 end of tracrRNA are
critical for Cas9-mediated genome modification (Cong et al.,
2013; Hsu et al., 2013).
Screens utilizing Cas9 have identified genes that are essential
for cell survival and genes involved in drug resistance in various
cell lines (Shalem et al., 2014; Wang et al., 2014; Koike-Yusa et
al., 2014; Zhou et al., 2014). In vivo pooled screens are chal-
lenging due to many factors, such as the complexity of the
library, limitations of virus delivery and/or cell transplantation,
uniformity of viral transduction at a low MOI, and the complex
dynamics and interactions of cells in animals. In this study, we
report a genome-wide Cas9 knockout screen in a mouse model
of tumor evolution. This screen provides a systematic pheno-
typic measurement of loss-of-function mutations in primary tu-
mor growth and metastasis.
RESULTS
CRISPR/Cas9 Library-Mediated Mutagenesis
Promotes Metastasis
We derived and cloned a cell line (Chen et al., 2014) from a
mouse non-small-cell lung cancer (NSCLC) (Kumar et al.,
2009). This cell line possesses an oncogenic Kras in conjunction
with homozygous p53 and heterozygous Dicer1 loss of function
(KrasG12D/+;p53/;Dicer1+/, denoted KPD) and is capable of
inducing tumors when transplanted into immunocompromised
mice (Chen et al., 2014; Kumar et al., 2009). We transduced
this cell line with a lentivirus carrying a Cas9 transgene fused
to a GFP and generated clonal cell lines (Cas9-GFP KPD) (Exper-
imental Procedures) (Figures S1A and S1B). A clonal Cas9-GFP
KPD cell line (clone 5) was selected to provide genetic and
cellular homogeneity for subsequent screens.
We utilized a pooled genome-wide mouse sgRNA library
(termed mouse genome-scale CRISPR knockout library A, or
mGeCKOa) containing 67,405 sgRNAs targeting 20,611 pro-
tein-coding genes and 1,175 microRNA precursors in the mouse
genome (Sanjana et al., 2014). The library also contains 1,000
control sgRNAs (termed non-targeting sgRNAs) designed to
have minimal homology to sequences in the mouse genome
(Sanjana et al., 2014; Shalem et al., 2014). We transduced the
Cas9-GFP KPD cell line with the mGeCKOa library in three inde-
pendent infection replicate experiments; for each replicate, the
library representation (cells per lentiviral CRISPR construct)
was greater than 4003 (Figure 1A) (Experimental Procedures).
After in vitro culture for 1 week, we subcutaneously trans-
planted 3 3 107 cells into the flanks of immunocompromised
Nu/Nu mice (Figure 1A). We transplanted the cells from each
infection replicate into four mice, using one mouse for early
tumor sequencing and three mice for sequencing of late-stage
primary tumor and metastases (Figure 1A). Both mGeCKOa-
transduced and untransduced Cas9-GFP KPD cells formed tu-
mors at the injection site (Figure 1B). Like most subcutaneously
transplanted tumors, these tumors were poorly differentiated.
The primary tumors induced by mGeCKOa-transduced cells
grew slightly faster than tumors from the untransduced cells at
an early stage (Figure 1C) (2 weeks post-transplantation) (paired
two-tailed t test, p = 0.05), but at late stages all tumors were
similar in size (paired two-tailed t test, p = 0.18 for data at
4 weeks, p = 0.6 for data at 6 weeks) (Figure 1C).At 6 weeks post-transplantation, we imaged the mice using
micro-computed tomography (mCT) and found tumors in the
lungs of the mice transplanted with mGeCKOa-transduced
Cas9-GFPKPD cells (mGeCKOamice), but not in themice trans-
planted with untransduced Cas9-GFP KPD cells (control mice)
(Figure 1D, Figure S1C). Mice were sacrificed and examined
for metastases in various organs. Under a fluorescent stereo-
scope at 63 magnification, metastases were visually detected
in the lung in 89% (8/9) of the mGeCKOa mice (Figure S1D).
The mGeCKOa mice on average had 80% of their lung lobes
positive for metastases (Figure 1E). In contrast, none (0/3) of
the control mice developed detectable metastases in the lung
(Figure 1E). At this time, metastases were not detected in the
liver, kidney, or spleen in either group (Figure 1F). These data
indicated that mGeCKOa library transduction enhanced the abil-
ity of the Cas9-GFP KPD cells to form metastases in the lung.
Dynamic Evolution of sgRNA Library Representation
during Tumor Growth and Metastasis
To investigate the sgRNA representation through different stages
of tumor evolution and to identify genes where loss of function
confers a proliferative or metastatic phenotype, we used deep
sequencing to readout the sgRNA representation (see Data S1
in Dataset S1). At 6 weeks post transplantation, we sequenced
the late-stage primary tumor and three random lobes from the
lung of each of the ninemGeCKOamice (Figure 1A) (Experimental
Procedures). In parallel, we also sequenced the mGeCKOa input
plasmid library, the pre-transplantation mGeCKOa-transduced
Cas9-GFP KPD cells (cultured in vitro for 7 days after trans-
duction), and early-stage primary tumors (2 weeks post trans-
plantation, one mouse from each infection replicate). In the cell
samples, the sgRNA representations showed high concordance
between technical replicates (correlation, r = 0.95 on average,
n = 3) and biological infection replicates (correlation, r = 0.84
on average, n = 3) (Figures 2A, S2A, S2B, and S2E). The sgRNA
representation of cell samples correlates highly with the plasmid
representation (correlation, r = 0.93 on average, n = 3) (Figures
2A, S2C, and S2E). Furthermore, different sgRNAs that target
the samegene are correlated in termsof rank change (correlation,
r = 0.49 on average, n = 3) (Figure S2D). Using gene set enrich-
ment analysis (GSEA), we found that the sgRNAs with signifi-
cantly decreased abundance in cells compared to plasmid are
enriched for genes involved in fundamental cellular processes,
such as ribosomal proteins, translation factors, RNA splicing fac-
tors, andRNA processing factors, indicating selection against the
loss of these genes after 1 week in culture (Figure S2F).
To investigate the sgRNA library dynamics in different sample
types (plasmid, pre-transplantation cells, early primary tumor,
late primary tumor, and lung metastases), we compared the
overall distributions of sgRNAs from all samples sequenced.
Cell samples clustered tightly with each other and the plasmid,
forming a cell-plasmid clade (Figures 2A and S2E). Early primary
tumor samples also clustered with each other and then with the
cell-plasmid clade, whereas late tumors and lung metastases
clustered together in a distinct group (Figures 2A and S2E).
The overlap of detected sgRNAs between different pre-trans-
plantation infection replicates is over 95% (Figure S3A). The de-
tected sgRNAs in the three infection replicates of early tumorCell 160, 1246–1260, March 12, 2015 ª2015 Elsevier Inc. 1247
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Figure 1. Tumor Growth and Metastasis in Transplanted Cas9-GFP KPD Cells with mGeCKOa Library
(A) Schematic representation of the loss-of-function metastasis screen using the mouse genome-scale CRISPR/Cas9 knockout library (mGeCKOa).
(B) Representative H&E stains of primary tumor from Nu/Numice subcutaneously transplanted with a Cas9-GFP KrasG12D/+;p53/;Dicer1+/ (KPD) NSCLC cell
line that was either untransduced or transduced with the mGeCKOa lentiviral library. Scale bar, 200 mm.
(C) Primary tumor growth curve ofNu/Numice transplantedwith untransduced cells (n = 3mice) ormGeCKOa-transduced Cas9-GFPKPD cells (n = 9mice). Error
bars indicate SEM.
(D) MicroCT 3D reconstruction of the lungs of representative mice transplanted with control (untransduced) and mGeCKOa-transduced (mGeCKOa) cell pools.
Lung metastases were identified and traced in each 2D section (green).
(E) Percent of lobes with metastases visible after dissection under a fluorescence stereoscope in Nu/Nu mice transplanted with untransduced Cas9-GFP KPD
cells (n = 3 mice) or mGeCKOa-transduced Cas9-GFP KPD cells with three independent infection replicate experiments (1, 2, and 3; n = 3 mice per replicate).
Error bars indicate SEM.
(F) Representative H&E stains from various organs of Nu/Nu mice subcutaneously transplanted with untransduced and mGeCKOa-transduced Cas9-GFP KPD
cells. Yellow arrow indicates a lung metastasis. Scale bar, 40 mm.
See also Figure S1.samples overlap 63%–76% with each other (Figure S3B). Early
primary tumors retained less than half (32%–49%) of the sgRNAs
found in the transplanted cell populations (Figures 2B, 2C, S3C,
and S3D). Compared to the cell populations, sgRNAs whose
targets are genes involved in fundamental cellular processes
are further depleted in early tumors (Table S1).
Interestingly, only a small fraction of sgRNAs (less than 4% of
all sgRNAs, or less than 8% of sgRNAs in the early primary tumor
of the corresponding replicate) were detected in the late-stage
primary tumor samples (Figures 2B, 2C, S3C, and S3D). The
sgRNA diversity (i.e., number of different sgRNAs detected)
further decreased in samples from lung metastases (Figures1248 Cell 160, 1246–1260, March 12, 2015 ª2015 Elsevier Inc.2B, 2C, S3C, and S3D). The lung samples retained %0.4% of
all sgRNAs in the mGeCKOa library, or%1.1% of sgRNAs found
in the early primary tumor of the corresponding replicate, with a
subset of highly enriched sgRNAs (Figures 2B, 2C, S3C, and
S3D). The global patterns of sgRNAdistributions in different sam-
ple types are distinct, as is evident in the strong shifts in the
respective cumulative distribution functions (Kolmogorov-Smir-
nov [KS] test, p < 1015 for all pairwise comparisons) (Figure 2D).
Enriched sgRNAs in Primary Tumors
Late primary tumors retain few sgRNAs (on average 813 ± 264
sgRNAs, n = 9 mice), with even fewer at high frequencies
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Figure 2. Representation of mGeCKOa Library at Different Stages of Tumor Growth and Metastasis
(A) Pearson correlation coefficient of the normalized sgRNA read counts from the mGeCKOa plasmid library, transduced cells before transplantation (day 7 after
spinfection), early primary tumors (2 weeks after transplantation), late primary tumors (6 weeks after transplantation), and lung metastases (6 weeks after
transplantation). For each biological sample type, three independent infection replicates (R1, R2, and R3) are shown. n = 1 mouse per infection replicate for early
primary tumors; n = 3 mice per infection replicate for late primary tumors and lung samples.
(B) Number of unique sgRNAs in the plasmid, cells before transplantation, early and late primary tumors, and lung metastases as in (A). Error bars for late primary
tumors and lung metastases denote SEM for n = 3 mice per infection replicate.
(C) Boxplot of the sgRNA normalized read counts for the mGeCKOa plasmid pool, cells before transplantation, early and late primary tumors, and lung me-
tastases as in (A). Outliers are shown as colored dots for each respective sample. Gray dots overlaid on each boxplot indicate read counts for the 1,000 control
(non-targeting) sgRNAs in the mGeCKOa library. Distributions for late primary tumors and lung metastases are averaged across individual mice from the same
infection replication.
(D) Cumulative probability distribution of library sgRNAs in the plasmid, cells before transplantation, early and late primary tumors, and lung metastases as in (A).
Distributions for each sample type are averaged across individual mice and infection replications.
See also Figures S2 and S3.(4 ± 1 sgRNAs with >5% of total reads) in each mouse (Figures
2B, 2C, S2C, S2D, 3A, and S4H). We used three methods to
identify enriched sgRNAs in late primary tumors: (1) sgRNAs
above a certain threshold, (2) top-ranked sgRNAs in the tumor
of each mouse, and (3) using false discovery rate (FDR), i.e.,
sgRNAs enriched compared to the distribution of the 1,000
non-targeting sgRNAs. All three methods generated similar re-
sults (Figure S4A). Taking the results from (3) as an example, a
total of 935 sgRNAs (targeting 909 genes) are enriched over
the non-targeting controls (FDR cutoff = 0.2%) in the late primarytumor of one or more mice (Figures 3B and 3C). These sgRNAs
are targeting genes highly enriched in apoptosis pathways (Table
S2), with many of them being pro-apoptotic, such as BH3 inter-
acting-domain death agonist (Bid), phosphatase and tensin ho-
molog (Pten), cyclin-dependent kinase inhibitor 2a (Cdkn2a),
and O-6-methylguanine-DNA methyltransferase (Mgmt), sug-
gesting strong selection for mutations that inactivate apoptosis
in primary tumor cells.
We identified 24 candidate genes that were targeted by two or
more independent sgRNAs enriched in late primary tumorsCell 160, 1246–1260, March 12, 2015 ª2015 Elsevier Inc. 1249
AB C
Figure 3. Enriched sgRNAs from the mGeCKOa Screen in Primary Tumors
(A) Pie charts of the most abundant sgRNAs in the primary tumors (at 6 weeks post-transplantation) of three representative mice (one from each replicate
mGeCKOa infection). The area for each sgRNA corresponds to the fraction of total reads from the primary tumor for the sgRNA. All sgRNAs withR2% of total
reads are plotted individually.
(B) Number of genes with 0, 1, 2, or 3 significantly enriched (FDR < 0.2% for at least onemouse) mGeCKOa sgRNAs targeting that gene. For genes/miRs with 2 or
more enriched sgRNAs, genes/miRs are categorized by howmany sgRNAs targeting that gene/miR are enriched as indicated in the colored bubbles adjacent to
each bar.
(C) Inset: waterfall plot of sgRNAs where multiple sgRNAs targeting the same gene are significantly enriched in primary tumors. Each sgRNA is ranked by the
percent of mice in which it is enriched. Only sgRNAs enriched in two or more mice are shown in the main panel. Main panel: enlargement and gene labels for
sgRNAs at the top of the list from the inset (boxed region).
See also Figures S3, S4, and S5.(Figures 3B and 3C). These genes were found to be mutated in
patients in many previously reported cancer sequencing studies
curated by cBioPortal (Cerami et al., 2012; Gao et al., 2013) (Fig-
ure S5A). For example, in somatic mutations identified by The
Cancer Genome Atlas (TCGA) for NSCLC, including adenocarci-
noma (LUAD) (Cancer Genome Atlas Research Network, 2014)
and lung squamous cell carcinoma (LUSC) (Cancer Genome
Atlas Research Network, 2012), 36% (107/407) of patients
have one or more of these 24 genes mutated (Figures S5B and
S5C). Several candidates were well-known tumor suppressors,1250 Cell 160, 1246–1260, March 12, 2015 ª2015 Elsevier Inc.such as Pten, cyclin-dependent kinase inhibitor 2b (Cdkn2b),
neurofibromin 2 (Nf2/Merlin), alpha-type platelet-derived growth
factor receptor (Pdgfra), and integrin alpha X (Itgax).
Enriched sgRNAs in Metastases
Wealso sequenced the sgRNAdistributions from three lung lobes
for each mouse transplanted with mGeCKOa-transduced
Cas9-GFP KPD cells. In each lobe, the sgRNA representation is
dominated by one or a few sgRNAs (Figures 4A, S3D, and S4I).
In each mouse, the lung sgRNA representation (average of
normalized sgRNA representations from three lobes) is also domi-
nated by a small number of sgRNAs (on average, 3.4 ± 0.4
sgRNAs with >5% of total reads) (Figure 4B), suggesting that me-
tastases were seeded by a small set of cells, which grew to domi-
nance over this timescale. Non-targeting sgRNAswere occasion-
ally detected in the metastases but were never observed at high
frequency (<0.1% of total reads in any lobe; Figures 2C, 4A and
4B, and S4I). These observations are consistent with our finding
that untransduced tumors are notmetastatic (Figure 1E), suggest-
ing that specific sgRNA-mediated mutations led to metastasis.
The sgRNA representations in the lung metastases are similar
to those in the late-stage primary tumors in several ways. First,
the detected sgRNAs in lung samples overlap significantly with
those in late tumor samples (chi-square test, p < 1015) (Fig-
ure S3E). Second, the number of sgRNAs detected in lung sam-
ples correlates, albeit weakly, with the number of sgRNAs
detected in late primary tumor samples (r = 0.42, F test, p =
0.097) (Figure S3F). Third, the abundance (number of reads) of
sgRNAs in the lung correlates positively with that in the late
primary tumors of the same mouse (correlation, r = 0.18 on
average, F test, p < 0.01, n = 9) (Figure S3G). Fourth, in most
mice (8/9), the lung metastasis enriched sgRNAs also occupy a
large fraction of reads in the late primary tumor of the same
mouse (Figure 4C, left panel), significantly larger than a random
sampling of the same number of sgRNAs from the mGeCKOa li-
brary (Figure 4C, right panel). These data indicate that mutants
with preferential ability to proliferate in late primary tumors are
more likely to dominate the metastases.
The three methods (threshold, rank, or FDR) of finding en-
riched sgRNAs in the lung metastases yield similar results (Fig-
ure S4B). Using the non-targeting sgRNA distribution to set a
FDR-based cutoff for enrichment, the enriched sgRNAs in
different lobes of the same mouse overlap with each other by
62% ± 5% (chi-square test, p < 1015) (Figure S4C), while
different mice show greater variability while still overlapping
significantly (29% ± 3%, chi-square test, p < 1015) (Figure S4D).
The overlap between sgRNAs in different biological/infection
replicate experiments when pooling enriched sgRNAs from all
mice in the same replicate is 54% (chi-square test, p < 1015)
(Figure S4E), suggesting that pooling sgRNAs from mice in the
same experiment facilitates the identification of shared hits.
These data suggest that the three independent experiments
reproducibly captured a common set of hits and provide a pic-
ture for in vivo experimental variation between different lobes,
different animals, and different infection replicates.
We found 147 sgRNAs enriched in more than one lobe, and
105 sgRNAs enriched in the lung of more than one mouse (Fig-
ures 4D and 4E). These include sgRNAs targeting Nf2, Pten,
tripartite motif-containing protein 72 (Trim72), fibrinogen alpha
chain (Fga), Bid, cyclin-dependent kinase inhibitor 2a (Cdkn2a),
zinc finger FYVE domain-containing 28 (Zfyve28), reproductive
homeobox 13 (Rhox13), and BRISC and BRCA1 A complex
member 1 (Babam1), as well as microRNA genes miR-152 and
miR-345. Intriguingly, a few sgRNAs targeting the Pol II subunits
and olfactory receptor are also enriched in the lung, possibly due
to off-target effects or unknown roles of these genes. For most
sgRNAs detected in lung metastases, the relative abundance
in metastases is lower than that in the late primary tumor of thesame mouse, with a metastasis-primary ratio (MPR) less than 1
(Figure S4F), likely due to more skewed distributions of sgRNAs
in the metastases compared to those in the late primary tumors.
A small subset of sgRNAs, however, are more abundant in me-
tastases than in primary tumors (MPR > 1) in multiple mice,
e.g., sgRNAs targeting Nf2, Trim72, prostaglandin E synthase 2
(Ptges2), or ubiquitin-conjugating enzyme E2G 2 (Ube2g2)
(Figure 4F).
For four genes, Nf2, Pten, Trim72, and Zfyve28, two indepen-
dent sgRNAs targeting different regions of the same gene were
enriched in lung metastases (Figure 4G). One of the Zfyve28-tar-
geting sgRNAs, however, is enriched in only one mouse,
whereas Nf2, Pten, and Trim72 all have two sgRNAs enriched
in multiple mice (Figure 4H). These three genes, several repre-
sentative genes with one frequently enriched sgRNA (Cdkn2a,
Fga, and Cryba4), and the two top-scoring microRNAs (miR-
152 and miR-345) were chosen to assay individually for primary
tumor growth and metastases formation.
Validation In Vivo Using Individual sgRNAs
For these eight genes (Nf2, Pten, Trim72, Cdkn2a, Fga, Cryba4,
miR-152, and miR-345), we cloned multiple sgRNAs targeting
each of them into the lentiGuide-Puro vector and transduced
them into the Cas9-GFP KPD cell line (Figure 5A) (Experimental
Procedures). As expected, these sgRNAs generated a broad
distribution of NHEJ-mediated indels at the target site when
examined 3 days post-transduction, with a bias toward deletions
(Figure 5B). For protein-coding genes, the majority (>80%) of in-
dels are out of frame, which potentially disrupts the protein func-
tions. For miR-152 and miR-345, the sgRNAs generated mostly
deletions (>90% of indels are deletions, average indel size –7 bp)
(Figure 5B), overlapping with the loop or mature microRNA se-
quences in the hairpins, which are structures required for matu-
ration of microRNAs. For proteins where specific antibodies are
available (Nf2 and Pten), we found that the majority of the protein
products were significantly reduced 1 week after lentiviral
sgRNA infection (Figure S6A).
When these single-sgRNA-transduced cells were trans-
planted into the flanks of immunocompromised mice, they all
formed tumors in situ. With two mice injected per sgRNA and
three sgRNAs per gene, all genes tested showed increased
lung metastasis formation compared to controls (untransduced
and non-targeting sgRNAs), with the most significant ones being
Nf2, Pten, and Cdkn2a (Fisher’s exact test, one-tailed, p < 103)
(Figures 5C and 5D). Fga and Trim72 also have effects onmetas-
tasis acceleration (Fga p = 0.001, Trim72 p = 0.046). Cryba4 is
not statistically different from controls (p = 0.1). sgRNAs target-
ingmiR-345 ormiR-152 significantly increased the rate ofmetas-
tasis (miR-345 p = 0.01,miR-152 p = 0.046). These data suggest
that loss-of-function mutations in any of Nf2, Pten, Cdkn2a,
Trim72, Fga, miR345, or miR-152 are sufficient to accelerate
the rate of metastasis formation in this genetic background.
Most genes targeted by single sgRNAs also contributed to
accelerated primary tumor growth compared to controls (Fig-
ure 5E). Nf2 and Pten loss of function dramatically speed up tu-
mor growth (KS test, p < 0.001) (Figure 5E); Cdkn2a-, Trim72-,
and Fga-targeting sgRNAs slightly accelerate primary tumor
growth (KS test, p = 0.003–0.01); Cryba4 has a marginal effectCell 160, 1246–1260, March 12, 2015 ª2015 Elsevier Inc. 1251
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Figure 4. Enriched sgRNAs from the mGeCKOa Screen in Lung Metastases
(A) Pie charts of the most abundant sgRNAs in three individual lobes of the lungs of two representative mice transplanted with mGeCKOa-transduced cells. The
area for each sgRNA corresponds to the fraction of total reads from the lobe for the sgRNA. All sgRNAs withR2% of total reads are plotted individually.
(B) Pie charts of the most abundant sgRNAs in the lung (averaged across three individual lobes) for the two mice shown in (A). All sgRNAs withR2% of average
reads are plotted individually.
(C) Left: percentage of late tumor reads for the significantly enriched (FDR < 0.2%) mGeCKOa sgRNAs found in the lung metastases (averaged across three
dissected lobes). Right: in purple, the percentage of late tumor reads for the significantly enriched (FDR < 0.2%) mGeCKOa sgRNAs found in the lungmetastases
(average across all mice, n = 9mice). In gray, the percentage of late tumor reads for random, size-matched samplings of sgRNAs present in the late tumor (n = 100
samplings). Error bars indicate SD.
(legend continued on next page)
1252 Cell 160, 1246–1260, March 12, 2015 ª2015 Elsevier Inc.
(KS test, p = 0.08); and neither miR-152- nor miR-345-targeting
sgRNAs promote primary tumor growth (KS test, p > 0.1). Over-
all, for the targets we examined using individual sgRNAs, the
number of lobes with lung metastases strongly correlates with
the terminal volume of the late primary tumor (or average primary
tumor growth rate) (correlation, r = 0.83, F test, p < 0.01) (Fig-
ure 5F), indicating at a single-gene level that mutant cells with
a stronger ability to promote primary tumor growth generate me-
tastases faster.
To analyze blood samples for the presence of circulating tu-
mor cells (CTCs), we designed a microfluidic device based on
the physical size of the Cas9-GFP KPD cells (Figures S6B and
S6C). We performed CTC capture with terminal blood samples
from mice injected with Cas9-GFP KPD cells transduced with
sgRNAs targeting Nf2, Pten, Trim72, Cdkn2a, and miR-152
and from mice injected with Cas9-GFP KPD control cells (un-
transduced or non-targeting sgRNA) (Figures S6C and S6D).
Mice transplanted with cells transduced with sgRNAs targeting
Nf2, Pten, Trim72, or Cdkn2a had a higher concentration of
CTCs as compared to controls (Figures S6D–S6G), consistent
with the higher rate of lung metastasis formation.
Competitive Dynamics of Top Hits Assessed Using
an sgRNA Minipool
To better understand the relative metastatic potential of multiple
genes from our genome-wide screen, we designed a targeted
pooled screen with a smaller library. This small library (termed
validation minipool) contains 524 sgRNAs targeting 53 genes
that had highly enriched sgRNAs in lung metastases in the
genome-wide screen (ten sgRNAs per gene for most genes)
plus 100 non-targeting sgRNAs.We also created a size-matched
library containing 624 non-targeting sgRNAs (termed control
minipool) (Figure 6A). Lentiviruses from these two pools were
used to transduce the Cas9-GFP KPD cells, which were cultured
in vitro for 1 week and then transplanted into Nu/Nu mice (Fig-
ure 6A). Both validation minipool- and control minipool-trans-
duced cells induced primary tumor growth at a similar rate
(Figure 6B). However, mice transplanted with validation minipool
cells had a dramatically elevated rate of lung metastasis forma-
tion (Figure 6C).
We sequenced the validation minipool plasmid library and the
transduced cells pre-transplantation, as well as the late-stage
primary tumors and whole lungs of the mice at 5 weeks post-
transplantation (see Data S2 in Dataset S1). The sgRNA repre-
sentations correlate strongly between technical replicates of(D) Inset: all sgRNAs found in individual lung lobes, ordered by the percent of lobes
sgRNAs for that lobe. Only sgRNAs enriched in two or more lobes are shown. Ma
inset (boxed region).
(E) Inset: all sgRNAs found in individual mice (averaged across three dissected lob
significantly enriched (FDR < 0.2%) sgRNAs for that mouse. Only sgRNAs enriche
sgRNAs at the top of the list from the inset (boxed region).
(F) Bottom:metastasis primary ratio (MPR) for the sgRNAs inmGeCKOawith enric
The sgRNAs are sorted by the number of mice in which the MPR for the sgRNA is
than 1. In both panels, individual sgRNAs are labeled by gene target.
(G) Number of genes with 0, 1, 2, or 3 significantly enriched (FDR < 0.2% for at l
enriched sgRNAs, gene names are indicated in the colored bubble adjacent to t
(H) Number of mice and percentage of mice in which each sgRNA was enriched
See also Figures S4 and S5.the transduced cell pool, late primary tumors, and lung metasta-
ses (Figures S7A and S7D). The sgRNA representation in the cell
sample strongly correlatedwith the plasmid (correlation, r = 0.91)
(Figures S7B and S7D). Almost all (99.4%) sgRNAs were recov-
ered in the plasmid and the cell population (Figure S7C). The
late primary tumors retained less than half of the sgRNAs, and
the metastases in the whole lung retained only a small fraction
(2%–7%) of all sgRNAs (Figure S7C). Enriched sgRNAs from
lung metastases clustered with each other and with late primary
tumors (Figure S7D). Similar to the genome-wide library, in this
validationminipool, the plasmid and cell samples had a unimodal
distribution of sgRNAs, whereas the late primary tumors and lung
metastases contained a bimodal distribution, with the majority of
sgRNAs being absent and a small fraction spanning a large range
of non-zero read counts (Figure 6D). Intriguingly, two mice re-
tained relatively high sgRNA diversity in late primary tumors (Fig-
ure 6D), likely due to dormant or slowly proliferating cells that
remained in low numbers during tumor growth. Similar to the
genome-wide library, large shifts in the sgRNA distribution exist
between different sample types (KS test, p < 1015 for pairwise
comparisons between the cell, primary tumor, and lung metasta-
ses, p = 0.02 between plasmid and cell) (Figure 6E).
In the validation minipool, the sgRNAs detected in the late
primary tumors or the lungs of five different mice significantly
overlap with each other (Figures S7E and S7F). The late primary
tumors and lung metastases are dominated by a few sgRNAs
(Figures 7A and S7G–S7I), suggesting that these sgRNAs
outcompete others during tumor growth and metastasis. With
the validation library, the sgRNA representations are highly
correlated between late primary tumors and lung metastases
(correlation, r = 0.55 on average, F test, p < 0.01, n = 5) (Fig-
ure 7B). The late primary tumors and lung metastases have
dozens of sgRNAs at moderate to high frequencies (Figures 7B
and 7C). Several genes have multiple independent sgRNAs
that are enriched in the lung over the primary tumor (MPR > 1),
such as Nf2 (eight sgRNAs), Pten (four sgRNAs), Trim72 (three
sgRNAs), Ube2g2 (three sgRNAs), Ptges2 (two sgRNAs), and
ATP-dependent DNA ligase IV (Lig4) (two sgRNAs) (Figures 7C
and 7D). Two Cdkn2a sgRNAs were present in both late primary
tumors and lungmetastases in twomice, but withMPR< 1. Fga-,
Cryba4-, miR-152-, and miR-345-targeting sgRNAs were not
found at high frequency in either late primary tumors or lung
metastases, suggesting that they are outcompeted by other
loss-of-function mutations (such as Nf2), which agrees with the
relatively reduced metastasis formation of these genes in thein which a particular sgRNAwas among the significantly enriched (FDR < 0.2%)
in panel: enlargement and gene labels for sgRNAs at the top of the list from the
es), ordered by the percent of mice in which a particular sgRNAwas among the
d in two or more mice are shown. Main panel: enlargement and gene labels for
hment inmetastases over late tumors (MPR > 1) observed in at least threemice.
greater than 1. Top: number of mice in which the MPR for this sgRNA is greater
east one mouse) mGeCKOa sgRNAs in the lung metastases. For genes with 2
he bar.
in the lung metastases for all genes with multiple enriched sgRNAs.
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Figure 5. Validation of Target Genes and MicroRNAs from mGeCKOa Screen Using Individual sgRNAs
(A) Schematic representation of lentiviral transduction of Cas9-GFP KPD cells with single sgRNAs designed to target one gene or miR. After puromycin selection,
the cell population was transplanted into Nu/Numice and also deep sequenced to examine the distribution of indels at the target site. After 5 weeks, the primary
tumor and lungs were examined.
(B) Histograms of indel sizes at the genomic locus targeted by a representative sgRNA for each gene/miR after 3 days of puromycin selection. Indels from sgRNAs
targeting the same gene were pooled (6 sgRNAs for each protein-coding gene; 4 sgRNAs for each miR).
(C) Representative H&E staining of lung lobes from uninjected mice (n = 3 mice), mice transplanted with cells transduced with Cas9 only (n = 5), and mice
transplanted with cells containing Cas9 and a single sgRNA (n = 6). Single sgRNAs are either control/non-targeting sgRNAs (n = 6 mice for control sgRNAs, 3
distinct control sgRNAs with 2 mice each) or targeting sgRNAs (n = 6 mice for each gene/miR target, 3 sgRNAs per target with 2 mice each). Blue arrows indicate
lung metastases. Scale bar, 10 mm.
(D) Percent of lung lobes with metastases after 6 weeks for the mice in (C). Error bars indicate SEM.
(E) Primary tumor growth curve ofNu/Numice transplanted with NSCLC cells transduced with Cas9 only (n = 5) or single sgRNAs (n = 6mice per gene/miR target,
3 sgRNAs per target with 2 mice each; n = 6 mice for control sgRNAs, 3 control sgRNAs with 2 mice each). Error bars indicate SEM.
(F) Correlation between primary tumor volume and percent of lobes with metastases for each gene in (D) and (E). Error bars indicate SEM.
See also Figure S6.
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Figure 6. Tumor Evolution and Library Representation in Transplanted Cas9-GFP KPD Cells with Minipool Libraries
(A) Schematic representation of the loss-of-function metastasis minipool screen. Briefly, Cas9-GFP KPD cells were transduced with either validation minipool
(524 gene-targeting + 100 non-targeting sgRNAs) or control minipool (624 non-targeting sgRNAs). After puromycin selection, the cell pools were transplanted into
Nu/Nu mice. After 5 weeks, validation minipool sgRNAs were sequenced from primary tumor and lung samples.
(B) Primary tumor growth curve of Nu/Numice transplanted with Cas9 vector + validation minipool cells (n = 5 mice) or Cas9 + control minipool cells (n = 5 mice).
Error bars indicate SEM.
(C) Percent of lung lobes with metastases after 6 weeks for the mice in (B). C, control minipool; V, validation minipool. Error bars indicate SEM.
(D) Boxplot of the sgRNA normalized read counts for the plasmid library, cells before transplantation, primary tumors, and lung metastases using the validation
minipool.
(E) Cumulative probability distribution of library sgRNAs in the validation plasmid pool, cells before transplantation, primary tumors, and lung metastases.
Distributions of primary tumor and lung metastases are averaged across five mice.
See also Figure S7.individual sgRNA validation. These results further validate
several of the top hits from the primary screen, using either
sgRNA dominance (e.g., Nf2, Pten, Trim72) or MPR (e.g., Nf2,
Trim72, Ube2g2, Ptges2). This validation minipool reveals the
dynamics of multiple competing mutants chosen from the pri-
mary screen hits and indicates that mutants with strong pro-
growth effects tend to enhance metastasis (Figure 7E).
TCGA Gene Expression of Screen Hits in Human
Lung Cancer
To assess the relevance of our mGeCKOa and validation mini-
pool screen hits (genes targeted by sgRNAs enriched in lung
metastases) to pathological metastasis in human cancer, we
performed gene expression analysis of the human orthologs
of these genes. We compared mRNA levels in metastatic
compared to non-metastatic primary tumors in patient samples
using TCGAmRNA sequencing data. We found that most (61%–
75%) of these genes are downregulated in metastatic tumors inNSCLC patients (Figures S5D and S5E; Table S6). These data
suggest that downregulation of these genes is selected for in
metastatic tumors from patients.
DISCUSSION
Pooled Mutagenesis in a Metastasis Model
Distal metastases develop as primary tumors shed CTCs into the
circulation, from which CTCs travel to the destination site, move
out of the blood or lymphatic vessels, and initiate clonal growth
(Valastyan and Weinberg, 2011; Vanharanta and Massague´,
2013; Weinberg, 2007). In this study, cancer cells transplanted
into the flanks of mice form primary tumors in situ, and cells
from this mass undergo the intravasation-circulation-extravasa-
tion-clonal growth cascade to form distal metastases (Francia
et al., 2011). The initial lung cancer cell line has little capacity to
form metastases; in contrast, after being mutagenized with the
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Figure 7. Enriched sgRNAs from the Validation Minipool Screen in Primary Tumors and Lung Metastases
(A) Pie charts of the most abundant sgRNAs in the primary tumor and the whole lung of two representative mice transplanted with validation minipool-transduced
Cas9-GFP KPD cells. The area for each sgRNA corresponds to the fraction of total reads from the tissue (primary tumor or lung metastases) for the sgRNA.
All sgRNAs withR2% of total reads are plotted individually.
(legend continued on next page)
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population formshighlymetastatic tumors. Thus, thesemutations,
acting in simple or complex pleiotropic ways, accelerate metas-
tasis. In this model, the effect of mutations onmetastasis strongly
correlates with their abundance in late-stage primary tumors.
sgRNA Dynamics during Tumor Evolution
The dynamics of the sgRNA population changed dramatically
over the course of tumor development andmetastasis, reflecting
the selection and bottlenecks of cellular evolution in vitro and
in vivo. After a week in culture, cells retained most of the sgRNAs
present in the plasmid library, with decreases in sgRNAs target-
ing genes involved in fundamental cellular processes. The distri-
bution of non-targeting control sgRNAs is almost identical to
those targeting genes, suggesting that the selective pressure
of in vitro culture alone does not radically alter sgRNA represen-
tation, similar to previous observations in humanmelanoma cells
(Shalem et al., 2014).
In contrast, less than half of the sgRNAs survive in an early-
stage primary tumor. This loss of representation occurs with
both gene-targeting sgRNAs and non-targeting control sgRNAs,
suggesting that random sampling influences sgRNA dynamics
during the transplantation and tumor initiation processes,
although we cannot exclude that some of the non-targeting
sgRNAs might have detrimental or pro-growth effects. We also
detected further dropout of genes involved in fundamental
cellular processes in early tumor samples compared to cell sam-
ples. Thus, it is likely that the sgRNA dynamics are influenced by
a combination of selection and random sampling during trans-
plantation and tumor initiation.
As primary tumors grow, the mutant cells proliferate and
compete as a pool. This creates strong selection for sgRNAs tar-
geting anti-apoptotic genes and other tumor suppressors. The
majority of the genetic diversity in early tumors is lost during the
subsequent 4 weeks of primary tumor growth in mice. Accord-
ingly, sequencing revealed a smaller set of dominant sgRNAs,
usually on the order of hundreds to a few thousand per mouse.
In addition, almost all of non-targeting sgRNAs are lost during pri-
mary tumorgrowth,which isconsistentwith selection for cellswith
special growth and survival properties. This observation is also
consistent with earlier transplantation studies by Kerbel and col-
leagues using small pools of randomly mutagenized cells, which
found that the majority of clonal variants detectable by Southern
blot disappearedwithin 6 weeks of primary tumor growth, leaving
one dominant clone (Korczak et al., 1988; Waghorne et al., 1988).
Each step toward metastasis has a bottleneck effect. In the
lung metastases, we detected very few sgRNAs at high abun-(B) Scatterplot of normalized sgRNA read counts in primary tumor and lung meta
dots indicate sgRNAs from different mice). log2 n.r., log2 normalized reads.
(C) log2 ratio of sgRNA abundance in the lung metastases over the primary tumo
sgRNA). Green dots are the 100 control sgRNAs. Dots with black outlines are n
sgRNAs for which more than one sgRNA targeting the same gene/miR is enrich
labeled with the gene/miR targeted. The lung-primary ratio is calculated for indiv
(D) Number of genes with 0 to 10 significantly enriched validation minipool sgRNA
miRs are categorized by how many sgRNAs targeting that gene/miRs are enrich
(E) Schematic illustration of tumor growth andmetastasis in the library-transduced
in the subcutaneously transplanted pool is selected over time for mutations that p
lung metastases.
See also Figure S7.dance. As with the primary tumor, we found only a few non-tar-
geting sgRNAs at low frequencies in metastases. Their presence
could be due to unknown off-target effects of these sgRNAs,
random shedding of CTCs in the primary tumor, or clustering
together with other strongly selected CTCs during metastasis
(Aceto et al., 2014).
Relevance of Screen Hits to Human Cancer
Several of the genes enriched in late-stage primary tumors are
associated with cancer, but their functions in tumor growth are
poorly understood. For example, Mgmt, a gene with two en-
riched sgRNAs, is required for DNA repair and is thus crucial
for genome stability (Tano et al., 1990). Mutation, silencing, or
promoter methylation of MGMT is associated with primary glio-
blastomas (Jesien-Lewandowicz et al., 2009). Med16, another
gene with two enriched sgRNAs, encodes a subunit of the
mediator complex of transcription regulation, which has been
recently implicated in cancer (Huang et al., 2012; Schiano
et al., 2014).
We found that the genes that are significantly enriched in lung
metastases largely overlap with those found in abundance in the
late primary tumor. Several of these hitswere validated in vivo us-
ing multiple individual sgRNAs, including Nf2, Pten, Cdkn2a,
Trim72, Fga, miR-152, and miR-345. Nf2, Pten, and Cdkn2a are
well-known tumor suppressor genes. Intriguingly, the NF2 locus
is mutated at only 1% frequency in primary tumors of human
NSCLC patients (LUAD and/or LUSC) (Cancer Genome Atlas
Research Network, 2012, 2014). Nf2 mutant mice develop a
range of highly metastatic tumors (McClatchey et al., 1998). It
is possible that NF2mutations influence metastases to a greater
degree than primary tumor growth, but this awaitsmetastasis ge-
nomics from patient samples. Pten mutations are also associ-
ated with advanced stages of tumor progression in a mouse
model of lung cancer (McFadden et al., 2014), and PTEN was
found to be mutated at 8% in adenocarcinoma patients
(LUAD). CDKN2A has been shown to be often inactivated in
lung cancer (Kaczmarczyk et al., 2012; Yokota et al., 2003).
Fga encodes fibrinogen, an extracellular matrix protein involved
in blood clot formation. Fgamutations have been found in various
cancer types in TCGA (Lawrence et al. 2013), as well as circu-
lating tumor cells (Lohr et al., 2014). Trim72 is an E3 ubiquitin
ligase, and its role in cancer metastasis is largely unknown.
Studies have shown that miR-152 and miR-345 are associated
with cancer and metastasis (Cheng et al., 2014; Tang et al.,
2011). FGF2 and BAG3, which promote metastasis, were pre-
dicted targets of miR-152 and miR-345; thus, loss of thesestases for all sgRNAs in the validation minipool for each mouse (different color
r (MPR) plotted against the abundance in the lung metastases (n = 5 mice per
on-control sgRNAs that target genes or miRs. Red dots indicate non-control
ed in the lung metastases over the primary tumor (i.e., log2(MPR) > 0) and are
idual mice, and these quantities are averaged across mice.
s in lung metastases. For genes/miRs with 2 or more enriched sgRNAs, genes/
ed, as indicated in the colored bubbles adjacent to each bar.
NSCLC transplant model. The initially diverse set of loss-of-functionmutations
romote growth of the primary tumor. A subset of these mutants also dominate
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microRNAs may lead to acceleration of metastases, likely due to
de-repression of these genes (Cheng et al., 2014; Tang et al.,
2011).
In our ownanalysis of TCGAsamples from lungcancer patients,
we observed downregulation of the human orthologs of the genes
identified in the genome-wide and validation minipool screens at
themRNA level inmetastatic tumors compared to non-metastatic
tumors, suggesting that these genesmay also be inactivated dur-
ing pathological metastasis. Human orthologs of these genes are
often found to be mutated in cancers. Moreover, these genes
have been implicated in various pathways and biological pro-
cesses in tumorigenesis and/or metastasis in human cancer (Ta-
bles S7A–S7C). However, most cancer sequencing studies
involve samples fromprimary tumors of patients. In the clinic, me-
tastases are rarely sampled. Future patient sequencing directly
from metastases may further connect genes identified in the
mousemodel to thosemutated or silenced in clinical metastases.Future In Vivo Functional Genomic Screens
Our study provides a roadmap for in vivo Cas9 screens, and
future studies can take advantage of this model to explore other
oncogenotypes, delivery methods, or metastasis target organs.
Genome-scale CRISPR screening is feasible using a transplant
model with virtually any cell line or genetic background (e.g., mu-
tations in EGFR, KRAS, ALK, etc.), including a large repertoire of
human cell lines from diverse cancer types (Barretina et al.,
2012). Other cell delivery methods, such as intravenous injection
or orthotopic transplantation, may help identify genes regulating
extravasation and clonalization. Examining samples from other
stages or sites, such as CTCs or metastases to other organs,
can provide a more refined picture of tumor evolution.
In addition to these parameters, several aspects of the screen
perturbations themselves can also be modified. Targeted drug
therapies or immunotherapies can be applied in conjunction
with the in vivo screening strategy to identify genes involved in
acquired resistance. Other screening technologies, such as
Cas9-mediated activation (Gilbert et al., 2014; Konermann
et al., 2015), can identify metastasis-regulating factors that act
in a gain-of-function manner. Activation screens that identify on-
cogenes, as well as dropout screens that identify genetic depen-
dencies, may facilitate identification of novel therapeutic targets.
Targeted subpool strategies can be used to reduce the library
size and facilitate further confirmation of primary screens. In a
customized library, genes can be chosen based on genomic
analysis, pathways, or clinical relevance for focused screening li-
braries. Additionally, application of pooled sgRNA libraries using
individually barcoded cells will allow quantitative assessment of
the robustness and significance of each candidate hit and will
enable analysis of the competitive dynamics among different
perturbations. With these promising future directions and the re-
sults of our study, Cas9-based in vivo screening establishes a
new platform for functional genomics discovery.EXPERIMENTAL PROCEDURES
Generation of Cas9-GFP Expression Vector
A lentiviral vector, lenti-Cas9-NLS-FLAG-2A-EGFP (lentiCas9-EGFP), was
generated by subcloning Cas9 into a lentiviral vector.1258 Cell 160, 1246–1260, March 12, 2015 ª2015 Elsevier Inc.Pooled Guide-Only Library Cloning and Viral Production
The Cas9-GFP KPD cell line was transduced at a MOI of 0.4 with lentivirus
produced from a genome-wide lentiviral mouse CRISPR knockout guide-
only library (Sanjana et al., 2014) containing 67,405 sgRNAs (mGeCKOa,
Addgene 1000000053) with at least 400-fold representation (cells per
construct) in each infection replicate. A detailed viral production and infection
protocol can be found in Extended Experimental Procedures.
Animal Work Statement
All animal work was performed under the guidelines of the MIT Division of
Comparative Medicine, with protocols (0411-040-14, 0414-024-17, 0911-
098-11, 0911-098-14, and 0914-091-17) approved by the MIT Committee
for Animal Care, and were consistent with the Guide for the Care and Use of
Laboratory Animals, National Research Council, 1996 (institutional animal wel-
fare assurance no. A-3125-01).
Mice, Tumor Transplant, and Metastasis Analysis in the Primary
Screen
Untransduced or mGeCKOa-transduced Cas9-GFP KPD cells were injected
subcutaneously into the right side flank of Nu/Nu mice at 3 3 107 cells per
mouse. Transplanted primary tumor sizes were measured by caliper. At
6 weeks post-transplantation, mice were sacrificed and several organs (liver,
lung, kidney, and spleen) were dissected for examination of metastases under
a fluorescence stereoscope.
Mouse Tissue Collection
Primary tumors and other organs were dissected manually. For molecular
biology, tissueswere flash frozenwith liquidnitrogenandground in24-well poly-
ethylene vials with metal beads in a GenoGrinder machine (OPS Diagnostics).
Homogenized tissues were used for DNA/RNA/protein extractions using stan-
dard molecular biology protocols. Tissues for histology were then fixed in 4%
formaldehyde or 10% formalin overnight, embedded in paraffin, and sectioned
at6mmwithamicrotomeasdescribedpreviously (Chenet al., 2014). Sliceswere
subjected to H&E staining as described previously (Chen et al., 2014).
Genomic DNA Extraction from Cells and Mouse Tissues
Genomic DNA from cells and tissues (primary tumors and lungs) was ex-
tracted using a homemade modified salt precipitation method similar to
the Puregene (QIAGEN/Gentra) procedure. The sgRNA cassette was ampli-
fied and prepared for Illumina sequencing as described previously (Shalem
et al., 2014). A detailed readout protocol can be found in Extended Experi-
mental Procedures.
Individual Gene and MicroRNA Validation
Six sgRNAs per protein-coding gene and four sgRNAs per microRNA gene
were chosen for validation using individual sgRNAs (Table S4). For protein-
coding genes, we cloned both the three sgRNAs from the mGeCKOa library
and three additional sgRNAs to target each gene. For microRNAs, we used
all four sgRNAs from the mGeCKOa library.
Validation and Control Minipool Synthesis and In Vivo
Transplantation
Validation and control minipools (Table S5) were synthesized using
array oligonucleotide synthesis (CustomArray) and transduced at
>1,000-fold representation in Cas9-GFP KPD cells. After 7 days in
culture, Cas9-GFP KPD cells transduced with the validation minipool or con-
trol minipool were injected subcutaneously into the right side flank of Nu/Nu
mice at 3 3 107 cells per mouse with five replicate mice. After 5 weeks, mice
were sacrificed, and primary tumors and lungs were dissected.
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